DIRS.INFO The most relevant business & tech news

☆ Eli Lilly receives approval for its weight-loss drug. But here's what could boost the stock next
▼ + stars: | 2023-11-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +4 min

Shares of Eli Lilly (LLY) jumped Wednesday after the U.S. government gave the green light for the company's blockbuster GLP-1 drug to be used as an obesity treatment. In a widely expected move, the U.S. Food and Drug Administration on Wednesday approved Eli Lilly's GLP-1 drug for weight loss. Eli Lilly said it will market the drug as an obesity treatment under the name Zepbound. Shares of Eli Lilly — which have climbed more than 67% year-to-date — soared nearly 2% Wednesday afternoon, to $611.36 apiece. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, LLY, Eli Lilly's GLP, Eli Lilly —, Eli Lilly's, Jim Cramer, Jim, Jim Cramer's, Cristina Arias Organizations: U.S, U.S . Food, Drug Administration, American Heart Association, Novo Nordisk, Novo, GLP, Nordisk's GLP, FDA, Nordisk, CNBC, Company, Pharmaceutical Locations: U.S, Danish, Alcobendas, Madrid, Spain

REUTERS/Sergio Perez Acquire Licensing RightsLONDON, Nov 7 (Reuters) - European Union (EU) energy ministers last month struck a deal to reform the bloc's power market. German power market forwards for 2024 and 2025LIGHT-TOUCH REFORMEuropean power prices have fallen a long way from their 2022 peaks, when the region was still reeling from the reduction in Russian gas supplies. EU member states were deeply split on proposals for more fundamental reform of Europe's power market to allow for a complete break of the gas-power price linkage. The hard-won compromise keeps the existing market mechanism, which its supporters claim is more efficient than other models in a liberalised electricity market. The bloc's power prices have historically been twice those of the U.S., but are now three or four times higher.

Persons: Sergio Perez, Teresa Ribera, Bernard Respaut, Mats Gustavsson, Boliden, Gustavsson, Respaut, Jan Harvey Organizations: REUTERS, Union, Spain's Energy, Producers, European Copper Institute, EU, Alcoa, PPA, European Commission, Metals, Reuters, Thomson Locations: Alcobendas, Madrid, Spain, Ukraine, San, EU, U.S, Ireland, Europe

☆ Promise around Eli Lilly's expected obesity drug, great earnings adds some $60 billion in market cap
▼ + stars: | 2023-08-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

(When excluding one-time divestment contributions and last year's Covid antibody revenue, Lilly's sales rose 22% on an annual basis.) Eli Lilly shares soared more than 16% to a new all-time high during Tuesday's session. LLY YTD mountain Eli Lilly's stock performance so far in 2023. Eli Lilly now expects adjusted earnings per share between $9.70 and $9.90, up significantly from the old guidance between $8.65 and $8.85. For its part, Eli Lilly is also studying Mounjaro's impact on other health outcomes including cardiovascular events.

Persons: Eli Lilly, Mounjaro, —, Jim Cramer's, Jim, Lilly's, Cheplapharm —, Lilly, Anat Ashkenazi, Ashkenazi, Eli Lilly's, Lilly Diabetes, Michael Mason, Mason, Verzenio, Trulicity, we've, David Ricks, Jim Cramer, Cristina Arias Organizations: Novo Nordisk, U.S, Amphastar Pharmaceuticals, Management, CNBC, Company, Pharmaceutical Locations: Indianapolis, North Carolina, U.S, Trulicity, Danish, Novo, Alcobendas, Madrid, Spain

☆ Bullish developments for three stocks across sectors — and our take, too
▼ + stars: | 2023-07-21 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Morgan Stanley analysts believe the market for obesity drugs is even larger than initially expected, a finding that aligns with our rosy outlook on Eli Lilly (LLY). The news: Obesity drugs could generate annual sales up to $77 billion in 2030, Morgan Stanley said Friday, a nearly 43% increase to the firm's previous forecast. Insurance reimbursement for obesity drugs has spread quicker than Morgan Stanley expected, which helped prompt the firm to update its multiyear sales outlook. However, there's been some concern that insurance companies would be hesitant to cover this new class of obesity drugs, which carry hefty price tags, along with side effects like nausea and vomiting. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Morgan Stanley, Eli Lilly, LLY, Lilly, Wegovy, Eli Lilly's, Morgan Stanley's, Jim Cramer's, we've, there's, Sartorius, Danaher, We've, We're, Lisa Su, Su, TSM, Apple's, There's, Jim Cramer, Jim, Cristina Arias Organizations: Club, Novo Nordisk, Wall, AMD, Devices, Club holding's, Nikkei Asia, Taiwan Semiconductor Manufacturing Company, Apple, Nvidia, Intel, CNBC, Company, Pharmaceutical Locations: U.S, Japan, Tokyo, Taiwan, China, Beijing, Arizona, Alcobendas, Madrid, Spain

☆ New data fortifies Eli Lilly's standing in the burgeoning market for weight-loss drugs
▼ + stars: | 2023-06-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

Eli Lilly (LLY) bolstered its position in the budding weight-loss drug market after new data showed its oral obesity pill was highly effective in a mid-stage study. Eli Lilly shares are taking a breather Monday, but we see no reason to join the sellers. Eli Lilly funded the trial. Eli Lilly stock is down about 1.3% Monday afternoon, likely on some profit-taking following a solid move up last week. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, LLY, orforglipron, Orforglipron, Eli Lilly's Mounjaro, Mounjaro, Jim Cramer, Lilly's, Geoff Meacham, Meacham, Lilly, It's, we've, Jim Cramer's, Jim, Cristina Arias Organizations: Club, New England, of Medicine, Nordisk, U.S . Food, Drug Administration, Novo Nordisk, Sunday, Bank of America, CNBC, UBS, Pfizer, Company, Pharmaceutical Locations: U.S, Alcobendas, Madrid, Spain

[1/5] Javier Ramiro, Co-Chief Scientific Officer of Spanish indoor hops farming start-up Ekonoke controls the plantation of hops in Alcobendas, Spain, March 23, 2023. "We're on a mission to save the world's beer," Ines Sagrario, chief executive and co-founder of Ekonoke, told Reuters. Strict hygiene measures such as protective clothing for staff ensure the space remains pest-free, taking the pesticides on which traditional farming often depends out of the equation. The most obvious challenge indoor farming faces, he said, is its high energy cost. "Demand from breweries is quite inelastic; you can't make beer without hops and they don't want to produce less," Sagrario said.

[1/2] The logo of Spanish energy, construction and services conglomerate Acciona, is projected on a wall during company's annual shareholder meeting in Alcobendas, outside Madrid, May 10, 2016. REUTERS/Sergio Perez/File PhotoMarch 31 (Reuters) - Spanish engineering firm Acciona (ANA.MC) and Germany's Nordex (NDXG.DE) said on Friday they teamed up to develop green hydrogen projects within the next 10 years in the United States, Latin America and Africa. Acciona owns a 41% stake in Nordex and its energy unit Acciona Energias (ANE.MC) will also participate in the joint venture. The joint company will not operate in Spain and Portugal, where Acciona Energias has an alliance with Plug Power (PLUG.O). Green hydrogen is seen as a potential solution to decarbonising heavy transport including commercial shipping.

Search resuls for: "Alcobendas"

7 mentions found